Biogen

Youtube Subscribe

Open: 257.47 Close: 257.88 Change: 0.41

You're losing the opportunity of using an AI to get informed about Biogen.

The game is changing. There is a new strategy to evaluate Biogen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, BIIB, Inc, company, develop, treatment, inc, and the …

Concept Map

Semantic Network

Stock Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, AVonEX, PLE.

Today's Summary

Biogen Inc. stock outperforms fr Friday when compared to competitors. At the time, Biogen had just launched a sweeping cost-reduction program that involved terminating around 1,000 employees in an effort to save $1 billion in operating expenses.

Today's News

Biogen inc. stock underperforms friday when compared to competitors - marketwatch.com. Biogen Inc. stock outperforms fr Friday when compared. to competitors. At the time, Biogen had just launched a sweeping cost-reduction program that involved terminating around 1,000 employees in an effort to save $1 billion in operating expenses by 2025. Biogen is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases. GlobalData tracks drug-specific phase transition and likelihood of approval scores. BTIG Sticks to Its Hold Rating for Biogen (BIIB) BTIG analyst Thomas Shrader maintained a Hold rating on Biogen yesterday. AE Wealth Management LLC has $428,000 stake in Biogen inc. (NASDAQ:BIIB), ae wealth management llc has. $428K in the company. Biogen Inc. (BIIB) NASDAQ: BIIB · IEX Real-Time Price · USD Add to Watchlist 257.88 -2.40 (-0.92%) At close: Jan 5, 2024, 4:00 PM 258.50 +0.62 (0.24%) After-hours: Jan. 5, 24/7. Biogen (NASDAQ:BIIB) Stock Price News Toggle navigation ☰ Features Pricing FAQ Stocks United States Manufacturing Drugs Biogen. Scribe Therapeutics, spun out of Jennifer Doudnas lab, emerged from stealth on 6 October with a $20-million series A round and a collaboration with Biogen. The California-based biotech will use that cash to continue developing their engineering platform, while bringing forward a pipeline that includes a Biogen-partnered ALS treatment. Biogen Inc (BIIB) news, articles, events & latest updates. Biogen is a biopharmaceutical company that discovers, develops, and delivers drugs and biosimilars for the treatment of various neurological and neurodegenerative diseases.

Stock Profile

"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts."

Keywords

This document will help you to evaluate Biogen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, BIIB, Inc, company, develop, treatment, inc, and the most common words in the summary are: biogen, scribe, stock, inc, news, therapeutic, best, . One of the sentences in the summary was: Biogen Inc. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biogen #scribe #stock #inc #news #therapeutic #best.

Read more →

Youtube Subscribe

---